- Home
- PERF vs MSLE Comparison
PERF vs MSLE Comparison
Compare PERF & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PERF | MSLE |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Taiwan | Canada |
| Employees | 353 | 17 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.1M | 146.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PERF | MSLE |
|---|---|---|
| Price | $1.71 | $7.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 297.4K | 100.0K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.93 | N/A |
| Revenue Next Year | $9.44 | N/A |
| P/E Ratio | $26.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.24 | $5.50 |
| 52 Week High | $2.67 | $13.39 |
Technical Indicators
Market Signals| Indicator | PERF | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 61.23 | 47.32 |
| Support Level | $1.68 | $6.67 |
| Resistance Level | $1.85 | $7.52 |
| Average True Range (ATR) | 0.06 | 0.63 |
| MACD | -0.00 | 0.29 |
| Stochastic Oscillator | 100.00 | 81.25 |
Price Performance
Historical ComparisonAbout PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.